Lepodisiran is an experimental medicine developed by Eli Lilly to lower lipoprotein(a), a genetic cholesterol risk factor linked to heart disease.
Clinical studies are being conducted at major academic medical centers, including Stanford University School of Medicine and the University of California, San Diego (UCSD), along with many international research sites.
Early trials showed that one or two doses can lower Lp(a) levels by nearly 94%.
The effects lasted for a year or longer.
Larger ongoing studies are now testing whether this treatment can help prevent heart attacks and strokes.
